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Abstract.  Mouse rnAb MS-l, raised against human 
spleen, detects an endothelial cell antigen abundantly 
expressed by the sinusoidal endothelia of spleen, lymph 
node, liver, and adrenal cortex, but absent from nonsi- 
nusoidal continuous endothelia in these organs.  Immu- 
noelectron microscopy of splenic tissue demonstrates 
that the MS-1  antigen is predominantly deposited at 
zones of intercellular contact between adjacent sinu- 
soidal endothelial cells, rnAb MS-1 also reacts with a 
variable proportion of high endothelial venules in ton- 
sil, but not in other lymphoid tissues, and with an in- 
terstitial dendritic cell population most abundant in 
placenta,  mAb MS-1  does not react with cultured rest- 
ing or mediator- activated human umbilical vein endo- 
thelial cells, dermal fibroblasts, peripheral blood mono- 
nuclear cells, or the cell lines U937, HL-60, K562 or 
Mo7E; it does react with the primitive myeloid cell 
line KG-1. rnAb MS-1 immunoprecipitates a major pro- 
tein of 216 kD and minor proteins of 320 and  120 kD 
from splenic extracts as analyzed by SDS-PAGE with 
reduction. These proteins are soluble in aqueous buffers. 
Immunoprecipitation  from KG-1 cell lysates detects 
four proteins of 280, 300, 205, and  120 kD; the 300-, 
205-, and  120-kD species, presumably corresponding 
to the 320-, 215-, and  120-kD species in spleen, re- 
spectively, are secreted into the media.  Under nonre- 
ducing conditions,  immunoprecipitates  from KG-1 cell 
lysates or conditioned media contain one predominant 
300-kD species; upon isolation and reduction, this 
300-kD species separates into the previously observed 
300-, 205-, and  120-kD species. Pulse-chase experi- 
ments and limited proteolysis peptide mapping  suggest 
that the 280-kD species is a precursor of the mature 
300-kD species which may be subsequently cleaved to 
yield the 205- and  120-kD species. Because of its size, 
solubility and expression pattern, the antigen recognized 
by mAb MS-1  is likely to be an extracellular matrix 
protein utilized by endothelial cells of contorted, large 
caliber, or leaky microvessels that lack a well-formed 
basement membrane. 
T 
HERE  is  remarkable  endothelial  heterogeneity  be- 
tween the blood vessel and lymphatic systems, along 
the length of the vascular tree and among endothelial 
cells in different organs. The criteria most widely applied to 
categorize different endothelia are whether endothelial  con- 
tinuity is maintained  and whether and how endothelial  dis- 
continuity  is achieved.  Continuity  is used to describe endo- 
thelia  that display both a continuous endothelial  cell layer 
and a well-formed,  continuous basement membrane as as- 
sessed by EM. Discontinuity  may refer either to a discontin- 
uous endothelial  cell layer or to a discontinuous  or missing 
basement membrane or to both. The vast majority of blood 
vessel endothelia belong to the continuous type. Of the blood 
vessel endothelia that are discontinuous,  bone marrow sinu- 
soidal endothelium forms a continuous endothelial cell layer, 
while hepatic and splenic sinusoidal endothelia form discon- 
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tinuous  endothelial  layers;  all three lack identifiable  base- 
ment membranes by EM. Lymphatic endothelia have an unin- 
terrupted endothelial cell layer, but are discontinuous  in that 
they attach to substratum by anchoring  fibrils rather than a 
well-formed basement membrane.  The wall of the lymphatic 
sinuses of the lymph node is special among the lymphatic en- 
dothelia,  consisting  of two layers  of Weibel-Palade  body 
containing  cells that in other respects closely resemble the 
lymph node parenchymal  reticular cells (35). 
In  this  spectrum  of  human  endothelial  subtypes,  the 
splenic  sinusoidal  endothelial  cells  probably  deviate  the 
most from the average endothelial  cell.  These cells have a 
unique  rod-shaped  appearance  and  contain  contractile, 
actin-myosin basal plates (6, 33, 34, 41, 53). The sinusoids 
are surrounded by bands of matrix  molecules called ring 
fibers (17, 28). The presence of sinusoids in the spleen is not 
a  stable phylogenetic  feature;  even closely related species 
like rat (sinusoid  positive)  and mouse (sinusoid  negative) 
can vary in their expression (46-49, 51). In those species that 
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arterial capillaries into the parenchyma (7, 24, 46--49) and 
either enters the sinusoids through their open ends (24) or 
squeezes into the sinusoidal lumen through interendothelial 
slits (32). During the latter process, the endothelial cells may 
contract and squeeze off intracellular inclusions (e.g., Heinz 
bodies) from erythrocytes. It is not known how contraction 
of sinusoidal endothelium is regulated or whether the ring- 
fibers are  sufficient to anchor  the endothelial  cells during 
contractions. 
Until now, no mAb probe has detected features unique to 
sinusoidal endothelia. In contrast, several mAbs can identify 
antigens  that  are  expressed  by all  continuous  endothelial 
cells.  Rat mAb  1F10 (23) is directed against a human en- 
dothelial cell-specific 150-kD cell surface protein, which is 
only weakly expressed on cultured human umbilical vein en- 
dothelial  cells  (HUVECs) I,  unless  they  are  placed  on  a 
basement  membrane  like  substrate  such  as  Matrigel  (S.. 
Goerdt and J. S. Pober, unpublished observations).  Mouse 
mAb hec7 (37) recognizes a human platelet-endothelial cell 
140-kD molecule (CD31) (38) that in HUVECs cultured on 
collagen relocates to the endothelial junctional complexes. 
Mouse mAb  Ec6C10  (26)  inhibits  Ca2+-dependent  homo- 
typic bovine endothelial cell adhesion, immunoprecipitates 
a  135-kD molecule, and is thus thought to recognize a bo- 
vine endothelial  cell cadherin.  The  lack of expression of 
these molecules in splenic and hepatic sinusoidal endothelia 
prompted  us  to  search  for  complementary  differentiation 
molecules that might be selectively expressed in discontinu- 
ous endothelia. 
mAb MS-1 was raised by immunizing  mice with human 
spleen and was chosen by immunohistochemical  screening 
for differential staining of sinusoidai and continuous endo- 
thelia in frozen sections of human spleen, mAb MS-1 detects 
a high molecular weight secreted protein antigen that is pref- 
erentially expressed by sinusoidal endothelia in normal hu- 
man  tissues,  i.e.,  spleen,  lymph  node,  liver,  and  adrenal 
cortex. We report here the tissue distribution and initial bio- 
chemical characterization  of this novel antigen. 
Materials and Methods 
Cells 
HUVECs were isolated and cultured by the method of Gimbrone (22) as 
modified by Thornton et al. (54). Human dermal fibroblast strains were es- 
tablished following  standard procedures (16). Peripheral blood mononu- 
clear cells were isolated by density gradient centrifugation of heparin-anti- 
coagulated  blood using Lymphocyte  Separation Media (Litton Bionetics, 
Kensington, MD). Human leukemia cell lines U937, HL-60,  K562, Mo7E, 
and KG-1 were a gift from James Griffin (Dana-Farber Cancer Institute, 
Boston, MA). A second KG-I strain and KG-1 variant cell line KG-Ia were 
kindly  provided by Donald Kufe (Dana-Farber Cancer Institute,  Boston, 
MA). Myeloid cell lines were propagated  in Iscove's Modified Dulbecco's 
Medium (Gibco Laboratories, Grand Island, NY), supplemented with 20% 
FCS and appropriate amounts of peuicillin/streptomycin. 
Mediators and Cell Treatments 
Recombinant human tumor necrosis factor-~, used at 100 U/mi, and recom- 
binant human interferon-v, used at 1,000 U/ml, were obtained from Biogen 
(Cambridge,  MA). Interleukin-lB and interleukin-4, used at 10 U/ml and 
1. Abbreviations used in this paper: HUVEC, human umbilical vein endo- 
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100 U/ml, respectively,  were purchased from Genzyme (Boston, MA). 
Transforming growth factor-~l, used at 10 ng/ml, was purchased from R&D 
Systems (Minneapolis, MN). PMA, dexamethasone, and diethylstilbestrol, 
each used at a concentration of 100 nM, were purchased from Sigma Chem- 
ical Co. (St. Louis, MO). Treatments of cells were performed with Cultures 
grown in Lab-Tek chambers (VWR Scientific, Boston, MA) for 24 h, after 
which the Lab-Tek slides  were washed in PBS and air-dried. 
Antibodies 
Murine mAb MS-1 was raised by immunizing 6-wk-old female Balb/c mice 
with whole human spleen, stored frozen at -700C, and sonieated before in- 
jection. The immunogen was initially applied in complete Freund's adjuvant 
(Sigma  Chemical Co.) and two boosts were administered in incomplete 
Fretmd's adjuvant (Sigma Chemical Co.) at 2-wk intervals.  Splenocyte fu- 
sion partners were NS-1 myeloma cells;  all procedures followed standard 
protocols as described (23). mAb MS-I was detected by immunoperoxidase 
screening (see below) of sections of human spleen. Isotyping was performed 
using a mouse mAb isotyping kit purchased from Amersham Corp. (Arling- 
ton Heights,  IL). Other antibodies used were the isotype-matehed  murine 
control mAb K16/16 (IgGlg), kindly provided by Donna Mendrick (Brig- 
ham and Women's Hospital, Boston, MA), murine mAb EI/I.2 flgG2b) 
against a mesenchymal  cell surface 96-kD glyeoprotein  (42), murine mAb 
Myl0 (Becton Dickinson Monoclonal Center,  Mountain View, CA) against 
CD34,  murine mAb and rabbit polyclonal  antiserum against  yon Wille- 
brand factor (vWF)  (Dakopatts,  Glostrup,  Denmark),  rat mAb MI/70 
against CDllb (Mac-1 a-chain; gift of Thnothy Springer,  The Center for 
Blood Research,  Boston, MA), rat mAb against CIM5 (Leucocyte  Com- 
mon Antigen; Zymed Laboratories, San Francisco,  CA), rabbit polycional 
antiserum against human glioma-derived tenascin (Gift of Harold Erick- 
son, Department of Cell Biology, Duke University Medical  Center,  Dur- 
ham, NC), and irrelevant rabbit serum as control. 
Immunohistochemistry 
Portions of human tissues,  derived from discarded tissue removed at sur- 
gery, or less commonly, necropsy, were snap frozen in liquid nitrogen and 
stored at -70°C. The following tissues (number of samples)  were exam- 
ined: spleen (9), liver (2), adrenal gland (7), lymph node (3), placenta (3), 
skin (3), tonsil (2), kidney (2), skeletal muscle (1), heart (1), brain (1), lung 
(1), small intestine (1), colon (1), and pancreas (1), Frozen sections of 6-10 
tim thickness were  prepared with a  Histostat 855  Cryostat Microtome 
(Reichert Scientific Instruments, Buffalo, NY), air-dried, and fixed for 10 
min in acetone.  Cytospin preparations of nonadherent cells and cultured 
cells on Lab-Tek slides (see above) were fixed similarly. Fixed slides were 
subjected to quenching of endogenous peroxidase in PBS containing 10 mM 
sodium azide and 0.1% hydrogen peroxide for 15 rain, followed~by  a prein- 
cubation step in 1% BSA (RIA grade, Sigma Chemical Co.) in PBS for 20 
rain. Primary antibodies, either as hybridoma culture supernataats or as 
concentrated antibody fluid or ascites diluted in 1% BSA in PBS, were ap- 
plied for 30 min at room temperature.  For double labeling, two primary an- 
tibodies made in different species (mouse/rat, mouse/rabbit) were mixed to- 
gether in 1% BSA in PBS and applied  simultaneously for 30 rain. After 
three 3-rain washes in PBS, an appropriate HRP-labeled secondary antibody 
(Jackson Immunoresearch, West Grove, PA), diluted 1:100 in 1% BSA in 
PBS, was applied for 30 min. For double labeling, two appropriate double- 
labeling grade,  species-specific  secondary antibodies (Jackson  Immuno- 
research, West Grove, PA), the first peroxidase-,  the second alkaline pbos- 
phatase-labeled, were each diluted together in 1% BSA in PBS to a final 
concentration of 1:50. After another washing step, peroxidase  was devel- 
oped with amino-ethyl-carbazole  (130 mg/l) in 0.1 M sodium acetate buffer 
for 10 rain, followed for double labeling by alkaline phosphatase develop- 
ment with Fast Blue RR salt (240 rag/l) in 0.01% Naphthol-AS-MX-phos- 
phate buffer  containing 600 mg/1 levamisole  for 30 rain. Single-labeled 
slides were counterstained in Gill's Hematoxylln. All slides were mounted 
in glycerol-gelatin. 
Immunoelectron Microscopy 
Normal human spleen obtained at staging laparotomy  was  immediately 
diced into 2-mm pieces and fixed in 4% paraformaidehyde  in 0.01 M phos- 
phate buffer (pH 7.2) with 7 % sucrose for 3 h at 4"C. Specimens were then 
washed in PBS three times (20 min with agitation for each wash) and snap- 
frozen.  Frozen sections prepared 6/~m thick were adhered to glass slides 
coated with 3-aminopropyltriethoxysilane,  and slides  were  subsequently 
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1:20. Immunologic staining was achieved by the use of a sensitive avidin 
biotin peroxidase complex (ABC) method (Vectastain Elite, Vector Labora- 
tories, Burlingame, CA). Briefly, sections were incubated with mAb MS-1 
hybridoma suporuatant or with mAb K16/16 control hybridoma supernatant 
for 1 h at room temperature; washed three times in PBS;  incubated with 
horse antimouse-biotinylated, afffinity-purified, spocies-specific  immuno- 
globulin (1:200)  for 30 min; washed for 20 min; and finally exposed  to 
preformed ABC (1:50) for 30 rain. After additional washing in PBS for 20 
rain, reaction sites were developed over a 3-rain interval using 3,3'-DAB (0.5 
mg/ml) and 0.01% H202  in 0.05 M  Tris HC1 buffer,  pH 7.6. Slides  were 
washed in PBS for 10 rain and fixed overnight in 2% ghitaraldehyde in 0.1 
M cacodylate buffer, pH 7.4. Specimens were finally dehydrated in graded 
ethanol and embedded in Epon using inverted beam capsules. Ultrathin sec- 
tions both unstained and stained with uranyl acetate were viewed with a 
Hitachi 7000 transmission electron microscope to visualize electron-dense 
DAB reaction product. 
Metabolic Labeling 
For total labeling of KG-1 cells and KG-1 cell culture supernatant, 1 ×  l0  s 
KG-I cells were incubated for 72 h in 20-50 mi of Iscove's Modified DUl- 
becco's Medium containing 20 % FCS and supplemented with a total of 5-10 
mCi of 35S-methionine and 35S-cysteine. For pulse-chase experiments, KG-1 
cell cultures were washed three times in RPMI 1640 without methionine 
and cysteine  (RPMI-) (Gibco Laboratories) and incubated for 30 rain in 
RPMI-. Ceils were then labeled in RPMI- supplemented with 10% FCS, 
and with 35S-methionine and 35S--cysteine (NEN, Boston, MA) at 0.4-2.0 
mCi/ml for 50 min, followed by a "chase  ~ in complete culture medium for 
the times indicated. When monensin (Sigma Chemical Co.) was included 
in experiments,  cells were preincubated for 1.5 h in complete culture medi- 
um containing monansin at a final concentration of 50 t~M. Subsequently, 
ceils were labeled as described for pulse-chase experiments in the continu- 
ous presence of monansin (50 t~M); the chase period was restricted to a 
maximum of 5 h because of the apparent toxicity of the compound at longer 
intervals. 
Immunoprecipitation of Unlabeled Antigen 
To immunoprecipitate antigen from spleen, frozen  splenic tissue blocks, 
,~0.15 cm  3 in size,  were first homogenized at 4°C into 1 ml of a  10-raM 
Tris-HCl pH 7.4/150 mM NaCI buffer, containing appropriate concentra- 
tions of the protease inhibitors soybean trypsin inhibitor, leupeptide and 
aprotinin (all from Sigma Chemical Co.), using a hand-held glass homog- 
enizer. Tissue disruption was completed by addition of 1 ml of 10% Triton 
X-114 (Sigma Chemical Co.), prepared according to the method of Bordier 
(9), to the spleen homogenate.  Where indicated, additional  phase separa- 
tion experiments with the Triton X-114 extracts were carried out as de- 
scribed by Bordier (9), layering the Triton X-114 extract on top of a 6% su- 
crose cushion, raising the temperature to 370C, spinning at 1,500 g for 20 
rain, and recovering the top and bottom  phases as the aqueous and detergent 
phase, respectively. The phase separation step was repeated two times. The 
resulting extracts were incubated on a rotator for 1 h and centrifuged for 
10 rain at 12,000 g in an Eppendorf centrifuge.  2 ttl of concentrated primary 
antibody fluid (anti-vWF mAb) or ascites (MS-l, K1616, El/1.2) were added 
to 150 #i of lysate. 
For preabsorption experiments, 20/~1 of anti-vWF mAb were added to 
500 ~1 of splenic extract, incubated for 2 h, and the immune complexes were 
removed with an excess of antiimmunoglobulin  Sepharose 4B beads (see be- 
low).  The remaining supernatant, preclcared of vWF, was divided in half 
and used for subsequent MS-1 antigen immunoprecipitation and for immu- 
noprecipitation with anti-vWF  mAb as a test of the completeness of the 
preclearing process. 
To immunoprecipitate from unlabeled KG-1 cells,  cells were washed 
three times in serum-free medium, and the cell pellet was snap-frozen  in 
liquid nitrogen. Cells were then directly lysed in the same buffer used to 
homogenize spleen containing in addition 2.5-5% Triton X-114. Lysates 
were incubated for 1 h and cleared by centrifugation. Where indicaled, 
phase separation experiments were carried out as described for the spleen 
extracts. 2 t~l of primary antibody were added to 300 t~l of lysate. To immu- 
noprecipitate from KG-1 cell culture medium, medium was centrifuged at 
1,500 g for 20 rain; in the case of medium, detergent was not used.  2 t~l 
of primary antibody were added to 2 ml of superuatant. 
For all immunoprecipitations, primary antibody incubations continued 
for 2-18 h. Cell lysates were centrifuged at 12,000 g for 10 rain and superoa- 
tants at 1,500 g  for 20 rain again.  Immune complexes  were collected on 
species-specific antiimmunnglobulin  Sepharose 413 beads (Cooper Biomed- 
icals,  Malvern, PA) for 2-4 h. The beads were washed ten times in 0.1 M 
Tris-HCl, pH 8.0, with 0.2% NP-40, and the antigen einted by boiling in 
either reducing or nonreducing SDS sample buffer, as indicated. Eluted an- 
tigen was electropboresed  on a 5 % polyacrylamide gel at 6.5 mA constant 
current for 18 h in the Laemmli buffer system; under these conditions, the 
front migrates offthe bottom of the gel, achieving optimal resolution in the 
high molecular weight range. The gel was fixed with 30% ethanol, 10% ace- 
tic acid and silver stained (two cycles,  as recommended by the protocol) 
using a kit obtained from Sigma Chemical Co. 
Immunoprecipitation of  MetabolicaUy 
Labeled Antigen 
Radioactively  labeled antigens from KG-1 cells and KG-I  cell culture 
medium were isolated as described for unlabeled antigens, except that im- 
mune complexes were ehited from the Sepharose beads by shaking them two 
times for 5 rain with 500/~1 of 0.1 M glycine-HCl, pH 2, supplemented with 
0.2 % NP-40 and 0.01% BSA. The samples were then precipitated by adding 
2× 200 ~1 of a 50% TCA solution to 1 ml of glycine eluate and incubating 
for 1 h at 4°C.  Precipitates were spun down at 12,000 g for 10 min, the 
supernatant was discarded, the pellet vortexed, washed in 1 ml of cold ace- 
tone, centrifuged again, and boiled in SDS-sample buffer, either containing 
or not containing 2-mereaptoethanol (2.5 %) as indicated. Samples were run 
on 7.5 % or 4-15 % gradient polyaerylamide gels at 4.5 mA constant current 
overnight.  Gels were fixed, equilibrated with Eniightning (NEN, Boston, 
MA), dried, and exposed for autoradingraphy to Kodak X-OMAT AR film 
(Eastman Kodak Co., Rochester, NY) at -70°C. Radioactivity in bands was 
quantified either by using a Betagen gel scanner (Betagen, Cambridge, MA) 
or by laser densitometry (Ultra-scan, Pharmacia Fine Chemicals, Piscata- 
way, NJ). For rerunning electrophoreticaUy  separated bands, the bands of 
interest were cut out of fixed and dried gels with the help of an autoradio- 
graph, put into wells of a second gel prefliled with either reducing or non- 
reducing sample buffer,  given 15 rain to equilibrate, and run at 40 mA 
constant current. Gels were fixed, dried, and exposed as described. In ex- 
periments designed to compare the amount of MS-1 secreted  vs. that re- 
tained by KG-I cells,  one half of a 3-d-labeled cell lysate was diluted to a 
volume (9.5 ml) equal to one half of the conditioned medium from the same 
culture.  Both samples were adjusted to equal Triton X-l14 concentration 
and immunoprecipitated in parallel. 
Limited Proteolysis Peptide Mapping 
Peptide mapping was carried out by limited proteolysis during reelectropho- 
resis as pioneered by Cleveland et al. (13). Briefly, metabolically labeled 
KG-1 lysate samples were irarnunnprecipitated  and subjected to SDS-PAGE 
as above. The gel was then equilibrated for 10 rain with Enlighming without 
prior fixation,  dried, and subjected to autoradingraphy.  Bands of interest 
were cut out of the dried gel at positions indicated by the autoradiograph. 
These gel slices,  without prior rehydration, were placed into the wells of 
a second gel prefilled  with 40 t~l of protease solution (0.5 or 0.05 mg of 
Staphylococcus aureus V8 protease (Cat.  #P-2922;  Sigma Chemical Co.), 
0.125 M Tris/HC1, pH 6.8, I mM EDTA, 0.1% SDS, 10% glycerol, and trace 
amounts of bromphenol blue dye) and allowed to equilibrate 30 min. An 
additionai 20 t~l of protease solution were added and the samples were run 
into the stacking gel at 25 mA constant eurrent. When the bromphennl blue 
dye front neared the interface between stacking and separating gels, current 
was turned off for 30 rain before electrophoresis was completed at 40 mA 
constant current. The final gel was fixed, dried, and exposed as described. 
Dot Blot Assay 
15 td of Mono-Q-purified human glioma-derived tenascin (150 ~g/ml; gift 
of Harold Erickson, Department of Cell Biology, Duke University Medical 
Center,  Durham, NC) and 15 td of purified plasma-derived fibronectin (2 
mg/ml; New York Blood Center, New York, NY), serving as a negative con- 
trol, were applied to a 0.45 nitrocellulose membrane (Schleicber & Schuell, 
Keene, NH). The membrane was dried, preincubated with 5 % nonfat dried 
milk and 20% FCS containing RPMI 1640 for 1 h, incubated with ascitic 
fluid or rabbit antisera for 1 h at a 1:1,000 dilution in 20% FCS containing 
RPMI 1640, washed with 10 mM Tris-HCl, pH 8/150 mM NaC1 with 0.05 % 
Tween 20, incubated for another hour with a 1:3,000 dilution of the appro- 
priate  alkaline  pbosphatase-labeled  secondary  antibody  (Jackson  Ira- 
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blue tetrazolium (NBT) and 5-bromo-4-chloro-3-indolyl-phosphate  diso- 
dium salt (BCIP) in alkaline phosphatase buffer (33 #1 of 50 rng/ml NBT 
dissolved in 70% dimethylformarnide  and 16.5 #1 of BCIP dissolved in 
double-distilled  water  added  to 5 ml to 100 mM Tris-HCl,  pH 9.5, 100 mM 
NaCI, 5 mM MgCI2, 1% NP-40). 
Results 
To identify molecular markers  of discontinuous endothe- 
lium, mAbs against whole human spleen were produced in 
mice and  screened for their ability to bind  selectively to 
splenic sinusoidal endothelial cells. From 473 hybridomas in 
one fusion, one hybridoma, producing antibody that stained 
the sinusoidal endothelium, but did not stain other endothelia 
or any other structure in the spleen, was selected and subse- 
quently cloned. This hybridoma, named MS-l, yielded sta- 
ble subclones that produced high titer antibody of IgG1K iso- 
type in either culture supernatant or ascites. 
Tissue Distribution 
In the spleen, mAb MS-1 strongly stained the sinusoidal en- 
dothelium in the red pulp outlining the  sinusoidal  spaces 
(Fig. 1, A and B). No staining was observed in the follicular 
areas nor in the capsular or trabecular systems including the 
larger arteries and veins (Fig.  1 A).  Double labeling with 
mAb 1F10 (23), specific for all continuous endothelial cells, 
whether arterial, arteriolar, capillary, or venular, revealed a 
staining pattern almost complementary for the two antibod- 
ies (Fig. 1 C). Only the endothelium of the transitional ven- 
ules, into which the sinuses open, exhibited limited double 
labeling (Fig. 1 D). However, MS-1 staining of these transi- 
tional venules was relatively weak compared to that of the 
sinusoidal endothelium. As expected, mAb MS-1 and anti- 
vWF antibodies double labeled the sinusoidal endothelium, 
while anti-vWF antibodies stained all other continuous en- 
dothelia and platelets as well. No double labeling between 
MS-1  and  anti-CDllb  antibodies  was  observed, the latter 
staining myeloid cells mainly in the red pulp and in the outer 
edge of the follicles. 
Ultrastructural examination (Fig. 2) confirmed that the an- 
tigen recognized by mAb MS-1 is, in spleen, present exclu- 
sively on sinusoidal endothelial cells. The antigen was ob- 
served in these cells both as small clusters of cytoplasmic 
reactivity, as well as about the entire perimeter of the plasma 
membrane (Fig. 2, A and B), including the abluminal sur- 
face (Fig. 2 E) where the cell interfaces with underlying in- 
terstitium. Staining was most intense at points of sinusoidal 
endothelial cell apposition (Fig. 2 F). Immunoelectron mi- 
croscopy corroborated complete absence of MS-1 reactivity 
on nonsinusoidal continuous endothelium in the spleen (Fig. 
2, B  and D). 
In  the  liver,  MS-l-positive cells  were  identified in  the 
sinuses (Fig. 1 E). MS-1 staining did not completely outline 
the  sinusoidal  channels,  but rather  appeared to  stain  the 
perinuclear region of single cells. As a result, it could not 
be decided from the single antibody staining pattern whether 
these cells were the hepatic sinusoidai endothelial cells or 
some  other  hepatic  sinusoidal  cell  population,  e.g.,  the 
Kupffer  cells. To address this question, we performed double- 
labeling experiments using a combination of MS-1 and anti- 
CDllb antibodies (Fig.  1 F) or MS-1  and anti-CD45 anti- 
bodies.  Such double-labeled sections of liver showed two 
distinct populations of cells adjacent to one another in the 
hepatic  sinuses:  the  Kupffer cells  expressing  CDllb  and 
CD45, and the hepatic sinusoidal endothelial cells express- 
ing the MS-1 antigen. Since vWF and the 1F10-antigen  are 
expressed at very low levels in the hepatic sinusoidal endo- 
thelial ceils and are not useful for double labeling in this or- 
gan, we cannot formally exclude that the MS-l-positive cell 
population might comprise some other sinusoidal element, 
e.g., the Ito- or fat-storing cell, but in the light of the overall 
staining pattern of mAb MS-I, we regard this possibility as 
highly unlikely. 
Staining of MS-1 in the adrenal gland was complex. This 
organ has a blood vascular system in its cortex whose vessels 
are of large caliber and irregular outline and are considered, 
for this reason, to be sinusoids. In contrast to the sinusoidal 
endothelial cells of spleen and liver, however, adrenal corti- 
cal sinusoidal endothelial cells sit on a well-formed basement 
membrane and form a continuous layer of endothelial cells, 
which express the continuous endothelial antigens CD31 and 
1F10. The MS-1 staining pattern in the cortical sinuses was 
focal (Fig. 1 G). Double labeling with MS-1 and 1F10 mAbs 
demonstrated that most MS-l-positive cells were also posi- 
tive for 1F10 (Fig. 1 H). In contrast, mAb 1F10 recognized 
much more of the total sinusoidal area than MS-1. 
The  lymph  node  has  a  delicate  system  of  lymphatic 
sinuses: the marginal sinus just below the capsule collecting 
the afferent lymph; the intermediate sinuses surrounding the 
follicles; and the medullary sinuses recollecting the lymph 
for outbound transport. In this organ, mAb MS-1 detected 
a network of lymphatic endothelial cells in all of the lym- 
phatic sinuses (Fig. 3 A). In transverse sections of lymphatic 
sinuses the MS-l-positive cells could be seen to line the ves- 
Figure 1. Tissue distribution of MS-1 antigen by immunohistochemistry I. Spleen (A-D), liver (E and F), and adrenal gland (G and H) 
were either labeled with mAb MS-1 using immunoperoxidase (red reaction produc0 and hematoxylin as a counterstaln (blue) (A, B, E, 
and G), or double labeled with mAb MS-I (red) and either anticontinuous endothelial cell mAb 1F10 (C, D, and H) or anti-CDllb mAb 
M 1/70 (F) using alkaline-phosphatase (blue reaction product). (A) Splenic sinusoidal endothelial cells in the red pulp stain strongly positive 
with mAb MS-l, while the follicular area (asterisk) and the endothelium of larger vessels (arrowhead) are not stained. (B) At higher 
magnification, mAb MS-1 outlines the interconnected system of splenic sinusoids. (C) Staining by mAb 1F10  of  the continuous endothelium 
of capillaries and larger vessels (blue) and by mAb MS-1 of  the splenic sinusoidal endothelium is complementary. (D) At higher magnifica- 
tion, the endotbelium of transitional veins, into which the strongly MS-l-positive splenic sinuses open, is predominantly stained by the 
anticontinuous endothelial cell mAb 1FI0 (blue, arrow) and concomitantly exhibits a minor amount of MS-1 staining. (E) mAb MS-1 stains 
the liver sinusoids. (F) mAb MS-1 stains the liver sinusoidal endothelial cells (red, arrow), while adjacent Kupffer cells are stained by 
anti-CDllb  mAb M1/70 (blue, arrowhead). (G) In the adrenal cortex, cells surrounding the endocrine ceils are stained by mAb MS-1. 
(H) The endotheliurrT  of  the adrenal cortical sinusoids is lightly stained by mAb IF10 (faint blue). A proportion of the 1F10  positive vascular 
structures seems to be double labeled by mAb MS-1. 
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of reactivity display electron dense DAB reaction product. Nuclei are stained with uranyl acetate.  The cytoplasm is unstained.  (A) Splenic 
sinusoidal endothelial  cell surrounding luminal space (L) shows DAB reaction product, indicating sites of MS-1 antigen reactivity, circum- 
ferentially  distributed  along the plasma membrane and in small aggregates  within the cytoplasm. (B) Small splenic arteriole  lined by en- 
dothelium devoid of MS-1 reactivity; granular material  within lumen (L) represents  serum protein. (C) Higher magnification  of luminal 
plasma membrane of sinusoidai  endothelial  cell depicted in A; note fine, electron dense DAB reaction product (arrowhead). (D) Higher 
magnification of arteriolar endothelial  cell depicted in B; there is no DAB reaction product decorating the endothelial  cell which rests 
upon a well-developed  basement membrane (arrows). (E) These sinusoidal endothelial  cells exhibited little luminal (L) reactivity, although 
multiple  foci (arrowheads) of reactivity are observed at interfaces  between abluminal  plasma membranes and interstitial  tissue.  A patchy 
cytoplasmic pattern is apparent above these regions.  (F) Plasma membrane activity for MS-1 antigen  was often strong and continuous 
in zones of apposition between adjacent sinusoidal  endothelial  cells. 
Figure 3. Tissue distribution  of MS-1 antigen by immunohistochemistry 12. Lymph node (A-D), placenta (E), tonsil (F), and KG-1 cells 
(G) were either labeled  with mAb MS-1 using immunoperoxidase (red reaction product) and hematoxylin as a counterstain (blue) (A, 
B, E, F, and G), or double labeled with mAb MS-1 (red) and either anticontinuous  endothelial  cell mAb 1F10  (D) or an anti-vWF polyclonal 
antibody (C) using alkaline-phosphatase  (blue reaction product). (A) In the lymph node, the marginal sinuses below the capsule (arrow- 
heads) and the intermediate sinuses surrounding the follicles stain strongly positive with mAb MS-1. (B) At higher magnification,  a trans- 
verse section of a lymphatic sinus shows MS-l-positive cells lining the vessel wall.  (C) Most of the MS-l-positive cells in the lymphatic 
sinuses  (red) are double labeled  with anti-vWF (blue), while continuous endothelia are exclusively  vWF positive.  (D) Staining  by mAb 
IF10 of the continuous endothelium of capillaries,  high endothelial  venules and larger vessels (blue), and by mAb MS-1 of the endothelial 
cells of  the lymphatic sinuses is complementary. (E) In placenta, an interstitial cell population, predominantly found in the villi,  is strongly 
stained by mAb MS-1. Endothelial  cells of placental  blood vessels are MS-I negative (arrowhead). (F) A tonsillar high endothelial  venule 
is reactive  with mAb MS-1 (center).  (G) KG-1 cells  exhibit  focal and granular MS-I staining  in ,'~40% of cells. Goerdt et al. Sinusoidal  Endothelial Cell High Mol Wt Protein  1431 Table L Reaction of mAb MS-1 with Human Cells and 
Cell Lines, Stimulated with Various Cytokines and Drugs 
Cell type  MS-1  staining 
HUVEC 
control 
+  interleukin-lB 
+  interleukin-4 
+  tumor necrosis factor-ix 
+  interferon-7 
+  transforming growth factor-B1 
+  PMA 
+  dexamethasone 
+  diethylstilbestrol 
Fibroblasts 
Peripheral blood mononuclear cells 
U937 
HL-60 
K562 
Mo7E 
KG-1  + 
KG-la  + 
sel wall (Fig. 3 B). Most of these MS-l-positive cells were 
found to coexpress vWF (Fig. 3 C), consistent with the ultra- 
structural finding that lymphatic sinus endothelial cells con- 
tain Weibel-Palade bodies (35) and, thus, underlining their 
endothelial  nature.  These  MS-l-positive  endothelial  cells 
did not coexpress the 1F10 antigen, which instead marked all 
continuous endothelia in the lymph node, including the high 
endothelial venules (Fig.  3 D).  Cells expressing CD1 lb or 
CD45 were only occasionally double labeled with MS-1 and 
were not very common in the lymphatic sinuses.  This is in 
accord with the suggestion proposing that the so-called sinus 
histiocytes, traversing the sinus lumen in cellular cords, may 
be a  subset of the sinus lining cells rather than true tissue 
macrophages (35,  57). 
In the tonsil, the only secondary human lymphatic organ 
without a blood vascular or lymphatic sinus system, a subset 
of postcapiUary venules, which appear to be the high en- 
dothelial venules of this organ, were stained with mAb MS-1 
(Fig. 3 F). It cannot be excluded, however, that MS-1 antigen 
expression on this subset of tonsillar endothelial cells is due 
to inflammatory induction, since both specimens of tonsil 
examined showed, at least focally, reactive changes, includ- 
ing neutrophil infiltration. 
The vasculature in all other organs examined was  MS-1 
negative. However, in several organs, mAb MS-1 was found 
to stain varying numbers of interstitial cells. MS-l-positive 
interstitial cells were most prominent in placenta (Fig. 3 E), 
but were also seen in skin, gut, pancreas, and cardiac and 
skeletal muscle.  In  contrast,  no MS-l-positive cells were 
found in brain. In double-labeling experiments, MS-l-posi- 
tive interstitial cells were demonstrated to be 1F10 negative. 
Thus,  these MS-l-positive cells could be lymphatic endo- 
thelial cells and/or subtypes of  tissue macrophages and inter- 
stitial dendritic cells (52),  such as placental macrophages 
(36) and dermal dendritic cells (39). 
Cells and Cell Lines 
HUVECs in  culture,  either unstimulated or stimulated by 
various cytokines and drugs,  and three different strains of 
Figure 4.  Comparison of antigen immunoprecipitated from unla- 
beled splenic extract (lanes 2 and 3), KG-1 cell lysate (KG-1L;  lanes 
4 and 5) and KG-1 cell-conditioned medium (KG-IM; lanes 6 and 
7) by mAb MS-1 (lanes 3, 4, and 6) and by isotype-matched irrele- 
vant mAb K16/16  as specificity control (lanes 2, 5, and 7). Samples 
were run after reduction on a 5 % polyacrylamide gel. The gel front 
was allowed to migrate off  the bottom of the gel to achieve optimal 
resolution in the high molecular weight range. Proteins were visual- 
ized by silver staining. MS-1 precipitates a predominant 215-kD 
and fainter 320- and 120-kD bands from splenic extract, a predomi- 
nant 300-kD, a thin 280-kD, and 205- and 120-kD bands from KG-1 
cell lysate, and 300-, 205-, and 120-kD bands from KG-1 cell-con- 
ditioned medium. 
dermal fibroblasts did not express the MS-1  antigen (Table 
I). In light of the presence of MS-l-positive interstitial cells 
in various organs, some of which may be bone marrow de- 
rived, peripheral blood mononuclear cells, myeloid leuke- 
mia cell lines U937,  HL-60, KG-1, and KG-la, erythroblas- 
toid leukemia cell line K562, and megakaryoblastic cell line 
Mo7E were examined (Table I). Of these cell types, only the 
early hemopoietic progenitor cell lines KG-1 and KG-la ex- 
pressed the MS-1 antigen in a somewhat focal and granular 
pattern (Fig. 3 G). No cell surface expression of  the MS-1 an- 
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ically labeled KG-1 cells, analyzed by SDS-PAGE (7.5% gel) and 
autoradiography. MS-1 immunoprecipitates are prepared from Tri- 
ton X-114 cell extracts before partition  (PRE; lane 1) and after 
phase separation into aqueous (AQ, lane 2) and detergent (DET, 
lane 3) phases. As quantified by gel scanning, *80% of the antigen 
partitions into the aqueous phase. In a separate experiment, sam- 
pies of Triton X-114 cell lysate before partition (KG-1L, lanes 4 and 
5) and of conditioned medium (KG-1M, lanes 6 and 7) from the 
same culture are immunoprecipitated in parallel with mAb MS-1 
(lanes 5 and 6) or with isotype-matched irrelevant mAb K 16/16 
(lanes 4 and 7). As quantified by gel scanning, ,,o40% of the total 
MS-1 antigen was recovered from the medium after a 72-h labeling 
period. 
tigen was seen in KG-1 cells analyzed using a fluorescence- 
activated cell sorter (data not shown). 
Identification of the Protein Recognized 
by mAb MS-I 
MAb MS-1 immunoprecipitated a 215-kD protein (reduced) 
from spleen extracts (Fig. 4), which was strongly stained by 
silver. The molecular weight of  this band was estimated from 
an electrophoretic migration slightly slower than laminin B1 
chain (210 kD) and slightly ahead of  the mature form of vWF 
(220 kD) (not shown). Fainter staining bands at '~320 and 
~120 kD (reduced) were also consistently identified in the 
immunoprecipitates from the spleen. No other silver-stained 
bands could be identified as specific in MS-1  precipitates. 
Most of the MS-1  antigen was found in the aqueous phase 
Figure 6. Effect of reduction upon MS-I antigen from metabolically 
labeled  KG-1 cells.  (A)  MS-1 immunoprecipitates  from  KG-1 
cell-conditioned  medium were subjected to SDS-PAGE (4-10% 
nonlinear gradient) with (lane 1) and without (lane 3) prior reduc- 
tion by 2-mercaptoethanol; control immunoprecipitates with iso- 
type-matched irrelevant mAb K  16/16 are shown in lanes 2 (re- 
duced) and 3 (nonreduced). Reduced precipitates show bands of 
300, 205, and 120 kD, whereas the unreduced sample shows one 
predominant species of "o300 leD. (B) A 300-kD unreduced MS-1 
immunoprecipitate cut out from a gel was reelectrophoresed (7.5  % 
gel) either with (lane 1 ) or without (lane 2) prior reduction. Reduc- 
tion of the 300-kD band yields three species, corresponding to the 
reduced 300-, 205-, and 120-kD species is seen in A. 
of Triton X-114 extracts, and antigen could also be extracted 
from spleen using aqueous buffers. Aqueously extracted an- 
tigen  remained  soluble  despite ultracentrifugation (1  h  at 
100,000 g). 
Immunoprecipitation from KG-1 cell lysates yielded four 
bands:  a  faint,  thin band  at  ~,280  kD,  stronger bands  at 
,'-300 and ~205 kD, and a broad band of variable intensity 
at ,M20 kD (all reduced) (Figs.  4  and 5).  Approximately 
80 % of the MS-1  antigen recovered after phase separation 
with Triton X-114, was found in the aqueous phase (Fig. 5). 
Analysis of KG-1 cell culture medium revealed that the 300-, 
205-,  and  120-kD species were secreted (Figs.  4  and  5); 
secreted MS-1 antigen accounted for ~40% of the total (cel- 
lular and secreted) MS-1 antigen synthesized during a 72-h 
labeling period (Fig. 5). MS-1 precipitates from the KG-1 su- 
pernatants  electrophoresed  without  prior  reduction,  ap- 
peared as one predominant 300-kD band (Fig. 6 A). When 
cut out from the gel and reelectrophoresed under reducing 
conditions, this unreduced 300-kD band separates into three 
major bands corresponding to the previously observed 300-, 
205-, and  120-kD species (Fig. 6 B). 
To further analyze the relationship among the immunopre- 
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were  labeled  with  35S-methionine and  35S-cysteine for 50  min 
(lanes 1-9) and subsequently chased in cold medium for 0 rain 
(lanes 1 and 2), 30 min (lane 3), 1 h (lane 4), 2 h (lane 5), 4 h 
(lane 6), 8 h (lane 7), 24 h (lane 8), and 48 h (lane 9). Cells were 
lysed and immunoprecipitation was carded out with mAb MS-I 
(lanes 2-9) or isotype-matched irrelevant mAb K16/16 as control 
(lane 1).  Samples were analyzed by SDS-PAGE (7.5% gel) and 
autoradiography. 
cipitated bands,  pulse-chase  experiments were  conducted 
(Fig. 7). The first MS-l-reactive species to appear at 0-30 
min of chase is the 280-kD band. This species peaks at 2-4 
h and is markedly diminished by 24 h of chase. The second 
species to appear is the 300-kD band, which is apparent by 
1-2 h of chase, peaks at 4-8 h, and persists at lower levels 
through 48 h.  The 205-kD species first appears at 8 h and 
reaches plateau by 24 h of chase. The 120-kD species is not 
well visualized in these experiments. If the cells were treated 
with monensin before metabolic labeling, no 300-kD protein 
species was observed, while there was marked accumulation 
of radioactivity in the 280-kD band (not shown). 
Finally, we used limited proteolytic digestion to analyze 
the structural relationship among the 300-, 205-, and 120-kD 
species (Fig. 8). The 300-kD species shares fragments with 
both the 205- and 120-kD species, while the 205- and 120- 
kD species appear different from each other. The compari- 
son of reduced and nonreduced species, the pulse-chase ex- 
periments, and the proteolysis data are most consistent with 
a  280-kD  precursor,  a  300-kD  mature form and variable 
cleavage of the 300-kD  species to yield 205- and  120-kD 
products. 
Comparison with Other High Molecular Weight 
Secreted Proteins 
Distribution among endothelial cells in various tissues, ex- 
Figure 8. Limited proteolysis of MS-1 antigen species from meta- 
bolically labeled KG-1 cell lysates by Staphylococcus aureus V8 
protease. The 300-kD (lanes 2 and 5), 205-kD (lanes 3 and 4) and 
120-kD (lanes 1 and 6) species were isolated by SDS-PAGE, sub- 
jected to Staphylococcus aureus V8 protease at high (lanes 1-3) or 
low (lanes 4-6) concentrations, reelectrophoresed on a 7.5-15% 
linear  gradient  gel,  and analyzed by autoradiography. Note the 
shared fragments of  the 300- and 205-kD species (arrowheads)  and 
of the 300- and 120-kD species (arrows). 
tracellular secretion, intercellular deposition, and high mo- 
lecular weight all suggest that the MS-1 antigen is likely to 
be an extracellular adhesion/matrix molecule. Of the various 
characterized extracellular adhesion/matrix molecules, only 
vWF and tenascin (reviewed in  19) share two key features 
with the MS-1 antigen: both are expressed by splenic sinusoi- 
dal endothelium (8,  10) and both are of similar size to the 
bands precipitated by mAb MS-1 (260- and 275-kD precur- 
sors and a 220-kD mature form for vWF; 320-,  230-,  and 
220-kD isoforms for tenascin) (4, 58). Therefore, we inves- 
tigated whether the MS-1  antigen could be a form of these 
molecules. As already described (see above), vWF is strongly 
expressed in sinusoidal endothelial cells of  the spleen, lymph 
node, and adrenal cortex, but not of liver. Furthermore, vWF 
is  expressed in  all continuous endothelial cells,  including 
HUVECs in culture, while it is not expressed in KG-1 cells 
(Table II).  In addition,  mature vWF  is  of slightly higher 
molecular weight than the MS-1 215-kD band in the spleen, 
as  demonstrated by direct comparison on SDS-page gels. 
Most convincingly, preabsorption of splenic extracts to re- 
move  all  immunoprecipitable vWF  does  not  remove  the 
MS-1 antigen (not shown). Thus, vWF and the MS-1 antigen 
are not identical. 
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Antigen Expression in Selected Cell Types 
Antibodies 
Cell  type  MS-1  tx-vWF  c~-Tcnascin 
HUVEC  -  +  - 
Fibroblasts  -  -  + 
KG-1  +  -  - 
Tenascin is a family of related molecules, some of which 
may as yet be uncharacterized.  Using a polyclonal antitenas- 
tin  antibody,  which  is  reported  to  mimic  staining  of all 
known antitenascin  mAbs,  including  an antitenascin  mAb 
specific for the 320-kD isoform (see ref. 30a), we found that 
all MS-l-positive structures in human tissues can be stained. 
However, minor differences in staining were noticed as the 
splenic sinusoids were not as crisp and well-outlined as with 
MS-l, and the liver sinusoids appeared more clearly visible 
as vascular channels with antitenascin than with MS-1. In ad- 
dition to the structures that apparently coexpressed the pro- 
teins, tenascin was expressed in many other structures, e.g., 
in  elongated elements  in  the  follicles of lymph  node and 
spleen, in cells at the outer edge of the follicles in tonsil, in 
the outer wall of arteries and arterioles, and at the epithelial- 
mesenchymal border in skin, tonsil and gut (as described in 
3, 31).  More critically, the MS-l-negative fibroblasts were, 
as expected (10), brightly tenascin positive, while the MS-l- 
positive KG-1 cells were tenascin negative (Table II). More- 
over, also expected from the literature (31), splenic tenascin 
was not solubilized using the Triton X-114 procedure applied 
for MS-1  immunoprecipitation  (data  not  shown).  Finally, 
Mono-Q-purified human glioma-derived tenascin,  reactive 
with various antitenascin mAbs and the polyclonal antitenas- 
cin antiserum (4), did not react with mAb MS-1 in a dot blot 
assay (not shown).  Thus, the known tenascin isoforms and 
the MS-1  antigen are not identical. 
Discussion 
We report here on the generation era mAb, designated MS-I, 
raised in the mouse against human spleen, that detects a pre- 
viously undeseribed antigen, expressed by the sinusoidal en- 
dothelia of spleen, lymph node, liver, and adrenal cortex, but 
not by nonsinusoidal  continuous endothelia and renal glo- 
merular endotheliurn.  Additional expression is seen in en- 
dothelial cells of tonsillar high endothelial venules and in an 
interstitial cell population in several organs such as placenta, 
skin, and gut, but not brain. Of several myeloid cell lines ex- 
amined, only the early myeloid cell lines KG-1 and KG-la ex- 
press and secrete the MS-1 antigen; no MS-1 antigen expres- 
sion is found on the cell surface of these cells. Preliminary 
studies in skin suggest that the MS-l-positive interstitial cells 
consist of two distinct populations:  vWF-positive lymphatic 
endothelial ceils and factor XHIa-positive dermal dendritic 
cells (L. J. Walsh, S. Goerdt, J. S. Pober and G. E  Murphy, 
manuscript in preparation). By ultrastructure, the MS-1 anti- 
gen in spleen appears to be deposited at zones of contact be- 
tween sinusoidal endothelial cells. 
The antigen  immunoprecipitated  from human  spleen by 
mAb MS-1 is a high molecular weight protein consisting of 
a prominent 215-kD and minor 320- and 120-kD proteins. 
mAb MS-1 precipitates a minor 280-kD and prominent 300-, 
205-, and 120-kD proteins from KG-1 cells, of  which the 300-, 
205-, and 120-kD species are secreted in substantial mounts. 
The differences in molecular weight between the similarly 
sized species in spleen and in KG-1 probably arise from slight 
differences in the posttranslational processing or from differ- 
ential splicing of mRNA in the two cell types, and it seems 
highly unlikely that they are unrelated,  cross-reacting pro- 
teins.  The 280-kD protein of KG-1 cells is not identified in 
immunoprecipitates from spleen. The amount of the 280-kD 
KG-1 protein is low, and thus may escape detection in cold 
splenic extracts.  Alternatively,  splenic MS-1  proteins may 
predominantly be solubilized from extracellular matrix de- 
posits, which would not be expected to contain the 280-kD 
species, since it seems not to be secreted. 
What  are  the  relationships  among  the  differently  sized 
MS-1 protein species? From the analysis of KG-1 cells, the 
most likely relationship of the proteins precipitated by mAb 
MS-1 is that of precursors and products. Specifically, we pro- 
pose that a 280-kD precursor is converted to a 300-kD spe- 
cies which, in turn,  is cleaved to 205- and 120-kD species, 
This interpretation  is supported by three lines of evidence: 
pulse-chase experiments,  comparison of reduced and non- 
reduced precipitates, and limited proteolytic fragmentation. 
First, in pulse-chase experiments, label appears to be chased 
from the 280-kD species into the 300-kD species and there 
is  extensive,  though  not  complete,  chase of radioactivity 
from the 300-kD species into the 205-kD species. Monen- 
sin, a drug known to affect transportation of proteins into the 
Golgi apparatus and to inhibit complex carbohydrate forma- 
tion in vWF and fibronectin biosynthesis (30, 58), inhibits 
the appearance of the 300-kD protein species and causes ac- 
cumulation of radioactivity in the 280-kD band, further sup- 
porting  the  interpretation  that  the  280-kD  protein  is  the 
precursor of the 300-kD protein.  The  120-kD protein spe- 
cies was not clearly seen in the late time points of the pulse- 
chase experiments;  this may be explained by the fact that 
there is less net radioactivity in these samples, that the 120- 
kD species labels less intensely than the other species, and 
that the radioactivity of the 120-kD species is spread over a 
range of molecular weight rather than being concentrated in 
a concise band. Second, studies comparing reduced and non- 
reduced precipitated forms of MS-1 antigen and conversion 
of unreduced  300-kD  to  205-  and  120-kD  species upon 
reduction also suggest a common origin of the 300-kD spe- 
cies and the smaller bands. These data further suggest that 
the 205- and  120-kD fragments must be held together by 
disulfide bonds. Finally, the common origin of the 205- and 
120-kD species from the 300-kD precursor is directly sup- 
ported by limited proteolysis peptide mapping.  Endogenous 
proteolytic conversion may be more efficient in splenic sinu- 
soidal endothelial cells than in KG-1 cells, accounting for the 
fact that  the  215-kD  protein  is  relatively  more  abundant 
(compared to the other protein species) in splenic extracts 
than  the 205-kD  species is in KG-1  cell lysate or culture 
medium. 
The antigen recognized by mAb MS-1 differs significantly 
from a number of other large extraceUular proteins described 
to date. In particular,  we have shown that the MS-1 protein 
is not identical with vWF or the three known isoforms of 
tenascin,  though it does share several features with them. 
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variant ED1 (40, 56), are clearly not identical to MS-1 be- 
cause of differences in molecular weight and/or tissue distri- 
bution. Other high molecular weight secreted proteins that 
were considered, but ruled out because of the lack of any 
substantial endothelial cell association, are: coagulation fac- 
tor VIII, thought to be synthesized preferentially in hepato- 
cytes (59);  coagulation factor V, synthesized in hepatocytes 
and megakaryocytes and found in spleen only in platelets 
(21); and the members of the high molecular weight tumor- 
associated glycoprotein family that are highly restricted to 
certain epithelia (1,  14). 
We have also considered whether MS-1 might be related 
to a previously described endothelial cell molecule. As noted 
earlier, mAbs 1F10 (23, and results), hec7 (37), and Ec6C10 
(26) recognize a subset of endothelia almost mutually exclu- 
sive with that detected by MS-1. mAbs o~HC1 (43) and B721 
(50) also share a lack of  reactivity in splenic and hepatic sinu- 
soids, and exhibit far more cross-reactions, e.g., with hairy 
cell leukemia ceils and epidermal basal cells and with acti- 
vated B- and T-cells,  smooth muscle cells,  and syncytio- 
trophoblast, respectively, mAb ENII/7/44  (25)  is directed 
against a subset of endothelia in inflammatory diseases and 
tumor tissues, but does not stain any normal endothelial cells, 
including splenic  or  hepatic  sinusoidal endothelia.  Liver 
sinusoidal endothelial cells and endothelial cells of high en- 
dothelial venules in secondary lymphatic organs express the 
monocyte-endothelial cell antigens CD14 (55) and HECA- 
452 (18), but these molecules are not found in splenic sinu- 
soidal endothelium. Of the antiendothelial mAbs that do re- 
act with splenic sinusoidal endothelium, BW200 (2), E431 
(50), and EN3/EN4 (15) are pan-endothelial markers. CD36 
(29),  a monocyte-platelet-endothelial cell-surface glycopro- 
tein of 90 kD functioning as a thrombospondin receptor, and 
the antigen recognized by mAb PAL-E (44), are expressed 
on all microvascular endothelia, including the splenic sinu- 
soidal endothelium, and to a lesser extent in the endothelium 
of larger vessels, especially larger arterioles and arteries. 
Expression of CD71, the transferrin receptor, shared among 
splenic sinusoidal (11) and brain capillary (27) endothelia in 
situ, may bear some functional significance in the splenic si- 
nusoids in light of their involvement in erythrocyte selection, 
pitting, and degradation. Expression of CD8 by the splenic 
sinusoidal endothelial cells,  as  detected by immunoenzy- 
matic staining with mAbs Leu2a OKT8 (11, 55), is unprece- 
dented not only among endothelial cells, but among all non 
T-cells,  and, if confirmed, could possibly be of great im- 
portance for sinusoidal endothelial cell biology. CD33 and 
CD34 (5,  12),  which, like MS-l, are somewhat selectively 
expressed in hemopoietic progenitor cells, differ from MS-1 
in molecular mass (70 and 110 kD, respectively) and tissue 
distribution. Interestingly, CD34 is an endothelial cell protein 
as well that is, unlike MS-l, preferentially expressed in situ 
in continuous type endothelial cell microvessels (20) and on 
abluminal endothelial cell microprocesses in tumor stroma 
(45),  but is absent from splenic (S. Goerdt and J. S. Pober, 
unpublished observations) and hepatic sinusoids (20). 
The function of the molecule recognized by mAb MS-1 is 
not yet known. A possible function may be inferred from the 
unique in situ distribution of this molecule and its biochemi- 
cal characteristics. The expression of MS-1 antigen groups 
together the sinusoidal endothelia that had not previously 
been thought to have much in common other than the fact 
that they are microvessels of large caliber and irregular out- 
line and (with the exception of the adrenal cortex) lack a 
well-formed basement membrane.  In preliminary studies, 
we have found that MS-1 antigen is also expressed by the en- 
dothelium of the bone marrow sinusoids, which also lack a 
basement membrane, and by the endothelium of certain tu- 
mor vessels, characterized by tortuosity and leakiness. The 
large size of MS-1 antigen, the secretion of the molecule by 
KG-1 cells, and the ultrastructural accumulation of the pro- 
tein at zones of intercellular contact between splenic sinusoi- 
dal endothelial cells all point to a role as an extracellular 
adhesion/matrix protein. We offer the hypothesis that MS-1 
protein serves an adhesive function for endothelial cells in 
those vessels which because of their irregular shape, large 
caliber, leakiness, or lack of proper basement membrane, 
must use macromolecules different from those utilized by 
continuous endothelia to  achieve  and  maintain  their  in- 
tegrity. 
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